Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at Jefferies Financial Group issued their Q3 2020 earnings per share estimates for shares of Harmony Biosciences in a report released on Monday, September 14th. Jefferies Financial Group analyst C. Howerton forecasts that the company will earn $0.12 per share for the quarter. Jefferies Financial Group has a “Buy” rating and a $51.00 price objective on the stock. Jefferies Financial Group also issued estimates for Harmony Biosciences’ Q4 2020 earnings at $0.32 EPS, FY2020 earnings at ($0.59) EPS, FY2021 earnings at $1.19 EPS, FY2022 earnings at $3.62 EPS, FY2023 earnings at $4.14 EPS and FY2024 earnings at $6.40 EPS.
Several other brokerages have also recently commented on HRMY. Piper Sandler started coverage on Harmony Biosciences in a research report on Monday. They issued an “overweight” rating and a $61.00 target price for the company. Goldman Sachs Group started coverage on Harmony Biosciences in a research report on Sunday. They issued a “neutral” rating and a $43.00 target price for the company.
Shares of HRMY stock opened at $36.48 on Wednesday. Harmony Biosciences has a one year low of $31.88 and a one year high of $47.37.
In related news, Director Jack Nielsen acquired 3,057 shares of the company’s stock in a transaction on Monday, August 24th. The stock was purchased at an average cost of $34.30 per share, for a total transaction of $104,855.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Holdings A/S Novo acquired 132,503 shares of the company’s stock in a transaction on Friday, August 21st. The shares were bought at an average price of $24.00 per share, with a total value of $3,180,072.00. Following the completion of the purchase, the insider now directly owns 4,277,300 shares of the company’s stock, valued at $102,655,200. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 138,296 shares of company stock valued at $3,380,687.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc was formerly known as Harmony Biosciences II, Inc and changed its name to Harmony Biosciences Holdings, Inc in February 2020.
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.